Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
Public ClinicalTrials.gov record NCT01100489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer
Study identification
- NCT ID
- NCT01100489
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Ductal Breast Carcinoma in Situ
- Estrogen Receptor-negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- HER2-positive Breast Cancer
- Invasive Ductal Breast Carcinoma
- Invasive Lobular Breast Carcinoma
- Male Breast Cancer
- Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate
- Mucinous Ductal Breast Carcinoma
- Papillary Ductal Breast Carcinoma
- Progesterone Receptor-negative Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer
- Tubular Ductal Breast Carcinoma
Interventions
- external beam radiation therapy Radiation
- questionnaire administration Other
- therapeutic conventional surgery Procedure
Radiation · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- Sep 30, 2011
- Completion
- Sep 30, 2011
- Last update posted
- Dec 7, 2011
2010 – 2011
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| UH-Chagrin Highlands | Orange | Ohio | 44122 | — |
| UH-Westlake | Westlake | Ohio | 44145 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01100489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2011 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01100489 live on ClinicalTrials.gov.